Innovating.works Conecta tu I+D

Showing 1 to 20 of 56 results

SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado

FIBROTARGET: Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases HUMANITAS MIRASOLE SPA participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies...
2023-04-24 - 2028-03-31 | Financiado

SYNTHEMA: Synthetic generation of hematological data over federated computing frameworks HUMANITAS MIRASOLE SPA participó en un HORIZON EUROPE: HORIZON-HLTH-2022-IND-13 Haematological diseases (HDs) are a large group of disorders resulting from quantitative or qualitative abnormalities of blood cells, lympho...
2022-11-10 - 2026-11-30 | Financiado

MATILDA: Microglia As conTroller of braIn metaboLism During Aging HUMANITAS MIRASOLE SPA tramitó un HORIZON EUROPE: ERC-2021-ADG Microglia represent the main brain residential immune cells. In the last years evidence emerged that, besides representing the first line o...
2022-07-25 - 2027-12-31 | Financiado

NEUROCOV: The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV HUMANITAS MIRASOLE SPA participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite th...
2022-05-20 - 2027-08-31 | Financiado

HARMONIA: Development of a Support System for Improved Resilience and Sustainable Urban areas to cope with Cli... HUMANITAS MIRASOLE SPA participó en un H2020: H2020-LC-CLA-2018-2019-2020 HARMONIA will leverage existing tools, services and novel technologies to deliver an integrated resilience assessment platform working on to...
2021-05-18 - 2025-01-31 | Financiado

Algae4IBD: ALGAE4IBD FROM NATURE TO BEDSIDE ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMA... HUMANITAS MIRASOLE SPA participó en un H2020: H2020-FNR-2020 Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural bi...
2021-05-03 - 2025-05-31 | Financiado

GenoMed4ALL: Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases HUMANITAS MIRASOLE SPA participó en un H2020: H2020-SC1-FA-DTS-2018-2020 GENOMED4ALL will support the pooling of genomic, clinical data and other -omics health data (data EHR, PET, MRI and CT , Next Generation Se...
2020-12-04 - 2024-12-31 | Financiado

COVID-X: COVID eXponential Programme HUMANITAS MIRASOLE SPA participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 COVID-X will bridge the collaboration divide between eHealth solution providers -with emphasis on lean startups and small and medium-sized e...
2020-10-13 - 2022-10-31 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... HUMANITAS MIRASOLE SPA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado

TRAIN-HEART: TRAIN HEART HUMANITAS MIRASOLE SPA participó en un H2020: H2020-MSCA-ITN-2018 TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who...
2019-04-08 - 2023-08-31 | Financiado

SUMO-PCDH10: Physiological consequences of Protocadherin 10 sumoylation on neuronal function. HUMANITAS MIRASOLE SPA tramitó un H2020: H2020-MSCA-IF-2018 Sumoylation is an essential post-translational modification that regulates a wide range of cellular functions. Interestingly, several protei...
2019-03-28 - 2021-08-31 | Financiado

Pituitary enhancers: Identification and functional validation of novel enhancer sequences involved in pituitary gland dev... HUMANITAS MIRASOLE SPA tramitó un H2020: H2020-MSCA-IF-2018 There is a fundamental gap in understanding how the GPR101 gene regulates human growth in physiological and pathological conditions. Childre...
2019-03-27 - 2022-03-15 | Financiado

LION-HEARTED: Light and Organic Nanotechnology for Cardiovascular Disease HUMANITAS MIRASOLE SPA participó en un H2020: H2020-FETOPEN-2018-2020 Cardiovascular (CV) disease is the leading cause of mortality and morbidity worldwide, with an increasing incidence in the aging population...
2019-01-16 - 2023-10-31 | Financiado

DaPhNIs: Role of the Maternal Gut Microbiota in Immune Activation at the Maternal Foetal Interface Impact on... HUMANITAS MIRASOLE SPA tramitó un H2020: H2020-MSCA-IF-2017 Preeclampsia is a leading cause of morbidity and mortality in pregnancy. Although the pathogenesis remains largely elusive, it is thought to...
2018-12-17 - 2021-07-15 | Financiado

BIORECAR: Direct cell reprogramming therapy in myocardial regeneration through an engineered multifunctional p... HUMANITAS MIRASOLE SPA participó en un H2020: ERC-2017-COG In BIORECAR I will develop a new breakthrough multifunctional biomaterial-based platform for myocardial regeneration after myocardial infarc...
2018-06-15 - 2024-12-31 | Financiado